Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Arbutus Biopharma Corp as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 112
- +14 vs. Q3 2023
- Shares held
- 79.0M
- +8.12M (+11.5%) vs. Q3 2023
- Total value
- $197.4M
- +$53.6M (+37.3%) vs. Q3 2023
- New holders
- 21
- 34 more added
- Sold out
- 7
- 29 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ABUS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 176 | $674.9M |
| Q1 2026 | 167 | $625.4M |
| Q4 2025 | 172 | $586.9M |
| Q3 2025 | 166 | $536.4M |
| Q2 2025 | 163 | $365.0M |
| Q1 2025 | 168 | $390.1M |
| Q4 2024 | 154 | $340.3M |
| Q3 2024 | 144 | $389.2M |
| Q2 2024 | 131 | $298.4M |
| Q1 2024 | 119 | $215.2M |
| Q4 2023 | 112 | $197.4M |
| Q3 2023 | 99 | $143.8M |
| Q2 2023 | 111 | $152.4M |
| Q1 2023 | 122 | $189.3M |
| Q4 2022 | 114 | $126.3M |
| Q3 2022 | 127 | $89.1M |
| Q2 2022 | 113 | $120.0M |
| Q1 2022 | 119 | $130.6M |
| Q4 2021 | 123 | $154.4M |
| Q3 2021 | 100 | $149.8M |
| Q2 2021 | 91 | $87.6M |
| Q1 2021 | 94 | $86.5M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Arbutus Biopharma Corp; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 1,537,924 | $3.84M | 0.00% | −45,648−2.9% | Reduced |
| Citadel Advisors LLC | 1,933,958 | $4.83M | 0.00% | −84,219−4.2% | Reduced |
| State Street Corp | 2,396,760 | $5.99M | 0.00% | +235,359+10.9% | Added |
| Geode Capital Management, LLC | 2,817,695 | $7.04M | 0.00% | +120,611+4.5% | Added |
| ADAR1 Capital Management, LLC | 3,468,824 | $8.67M | 3.88% | +3,468,824 | New |
| Hudson Bay Capital Management LP | 4,139,904 | $10.3M | 0.09% | −10,000−0.2% | Reduced |
| Woodline Partners LP | 4,719,903 | $11.8M | 0.13% | 00.0% | Unchanged |
| Vanguard Group Inc | 5,988,883 | $15.0M | 0.00% | +40,861+0.7% | Added |
| Morgan Stanley | 6,984,112 | $17.5M | 0.00% | +1,722,982+32.7% | Added |
| Two Seas Capital LP | 9,041,927 | $22.6M | 5.57% | +761,109+9.2% | Added |
| BlackRock Inc. | 10,390,300 | $26.0M | 0.00% | +116,159+1.1% | Added |
| Whitefort Capital Management, LP | 13,197,062 | $33.0M | 21.03% | +1,301,585+10.9% | Added |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −264,441−100.0% | Sold out |
| Kepos Capital LP | 0 | $0 | 0.00% | −155,691−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −98,000−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −40,598−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −40,040−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −13,810−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −1,909−100.0% | Sold out |
| Pathstone Family Office, LLC | – | – | – | – | Not filed |